What is Twist Bioscience?
Twist Bioscience operates at the vanguard of synthetic biology, specializing in the large-scale, high-precision manufacturing of synthetic DNA. By leveraging a proprietary silicon-based platform, the company provides researchers across life sciences, medicine, agriculture, and industrial biotechnology with the tools necessary to accelerate innovation. Its market position is defined by its capacity to deliver high-quality, reliable DNA at unprecedented speed and scale, effectively lowering the barriers to entry for advanced genetic research and drug development. The company's ability to integrate its technology into complex workflows has made it an essential partner for organizations seeking sustainable and scalable biological solutions.
How much funding has Twist Bioscience raised?
Twist Bioscience has raised a total of $728.7M across 14 funding rounds:
Multiple Rounds
$50.2M
Series C
$37M
Series D
$61M
Debt
$20M
Series E
$60M
Share Placement
$50M
Stock Offering
$69M
Stock Offering
$84.1M
Multiple Rounds
$297.4M
Series A (2014): $9.1M with participation from Undisclosed
Series B (2014): $26M led by Paladin Capital Group, ARCH Venture Partners, Tao Invest, and Yuri Milner
Grant (2014): $5.1M supported by DARPA
Debt (2014): $10M featuring Silicon Valley Bank
Series C (2015): $37M backed by Foresite Capital Management, ARCH Venture Partners, Illumina Inc., Tao Invest, Fidelity Management & Research Company, Paladin Capital Group, and Yuri Milner
Series D (2016): $61M with participation from ARCH Overage Fund, WuXi Healthcare Ventures, Tao Invest, ARCH Venture Partners, Paladin Capital Group, Cormorant Asset Management, Boris Nikolic, Yuri Milner, Foresite Capital Management, Illumina Inc., Merieux Development, and Fidelity Management & Research Company
Debt (2016): $20M led by Silicon Valley Bank
Series E (2017): $60M supported by KANGMEI Group, NFT Investment Limited, Ditch Plains Capital Management, 3W Partners Capital, Biomatics Capital, FIS Global, Bay City Capital, and Reinet Fund
Share Placement (2018): $50M featuring Undisclosed
Stock Issuance/Offering (2018): $69M backed by Undisclosed
Stock Issuance/Offering (2019): $84.1M with participation from Undisclosed
Stock Issuance/Offering (2020): $50M led by Undisclosed
Stock Issuance/Offering (2020): $140M supported by Undisclosed
Stock Issuance/Offering (2020): $107.4M featuring Undisclosed
Key Investors in Twist Bioscience
ARCH Venture Partners
A leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs to commercialize innovations.
Paladin Capital Group
A global multi-stage investment firm specializing in venture capital and growth financing, providing strategic guidance and operational support to scale companies across diverse sectors.
Foresite Capital Management
A multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data to address significant unmet needs.
What's next for Twist Bioscience?
Following its recent major strategic investment, Twist Bioscience is well-positioned to further expand its manufacturing capabilities and deepen its penetration into high-growth sectors such as personalized medicine and synthetic biology-driven drug discovery. The company's historical reliance on a mix of venture capital, debt financing, and public market offerings suggests a sophisticated approach to capital management. Moving forward, the firm is expected to leverage its robust balance sheet to enhance its R&D pipeline, potentially exploring new frontiers in data storage and advanced therapeutics. As the demand for synthetic DNA continues to rise, Twist Bioscience remains focused on maintaining its competitive edge through operational excellence and strategic partnerships that solidify its role as a foundational infrastructure provider for the global biotechnology ecosystem.
See full Twist Bioscience company page
